Investigators propose a descriptive pharmacokinetic study of the serum hormone levels of
estrogen and progesterone with extended use (12 weeks) of the contraceptive patch. The
primary objective is to assess the change in serum Ethinyl Estradiol (EE2) levels over 12
weeks of continuous contraceptive patch use. Additional objectives include assessing the EE2
area under the curve (AUC) during the study time period, as well as Norelgestromin (NGMN)
levels and NGMN AUC over the 12 weeks of continuous contraceptive patch use.